Long-stalled proposals for topical drug additions to the US Food and Drug Administration's OTC monograph could begin making progress as the agency offers private meetings with sponsors on details of their maximal usage trials (MUsT).
A proposed final sunscreen monograph published in February provided parameters for sponsors' work on time and extent applications, but the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?